Table 2

Multivariate linear regression analysis of dopamine transporter availability in each striatal subgroup

Striatal subgroupAnterior caudatePosterior caudateAnterior putamenPosterior putamenVentral putamenVentral striatum
F=16.16, p<0.001F=15.21, p<0.001F=5.148, p<0.001F=2.406, p=0.021F=4.316, p<0.001F=7.784, p<0.001
βP valueβP valueβP valueβP valueβP valueβP value
Age at symptom onset−0.356<0.001−0.330<0.001−0.1370.0180.0120.841−0.1210.039−0.252<0.001
Female0.256<0.0010.245<0.0010.1690.0020.1120.0450.1400.0110.1230.020
Disease duration−0.0810.100−0.0300.538−0.0320.553−0.0180.741−0.0710.192−0.0990.062
Motor subtype
TDRefRefRefRefRefRef
 PIGD/indeterminate−0.0370.450−0.0810.100−0.1390.010−0.1460.009−0.1170.032−0.1250.018
BMI0.0180.715−0.0110.817−0.0070.891−0.0140.8070.0050.9200.0120.818
WMH volume−0.0470.350−0.0280.5850.0050.9220.0250.666−0.0340.549−0.0810.140
CPV−0.1340.012*−0.1620.002*−0.1330.024*−0.1250.039*−0.1250.035*−0.0900.117
  • Results of multivariate linear regression analysis for the striatal subgroup after controlling for age at symptom onset, sex, disease duration, motor subtype, BMI and WMH volume.

  • *P<0.05 after correction for multiple comparisons using the FDR method.

  • BMI, body mass index; CPV, choroid plexus volume; FDR, false discovery rate; PIGD, postural instability and gait difficulty; TD, tremor dominant; WMH, white matter hyperintensity; β, standardised beta coefficient.